Publications by authors named "Victor Baba Oti"
Traditionally, antiviral drugs target viral enzymes and or structural proteins, identified through large drug screens or rational drug design. The screening, chemical optimisation, small animal toxicity studies and clinical trials mean time to market is long for a new compound, and in the event of a novel virus or pandemic, weeks, and months matter. Small interfering RNAs (siRNAs) as a gene silencing platform is an alluring alternative.
View Article and Find Full Text PDFIntranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape.
Expert Rev Anti Infect Ther
August 2024
Article Synopsis
- Respiratory syncytial virus (RSV) primarily impacts vulnerable populations, leading to bronchiolitis and respiratory problems, yet effective antivirals have been challenging to develop despite recent RSV vaccine approvals.
- The newly approved nirsevimab shows promise for use as a prophylactic treatment, while current therapeutics are often delivered via IV or IM rather than more convenient IN methods.
- Research is increasingly focusing on intranasal (IN) antiviral therapies to target RSV directly in the respiratory tract, aiming to lessen illness severity and halt the spread of the virus more effectively.
Article Synopsis
- Around 70% of cervical cancer cases globally are linked to HPV-16 and HPV-18, but there's limited data on HPV in Central Nigeria, leading to a study on HPV-16 IgG prevalence and risk factors among women.
- A total of 400 women aged 15-49 participated, with 32% testing positive for HPV-16 IgG; seroprevalence varied significantly by age, peaking at 50% in the 15-19 age group.
- Key risk factors identified included age, occupation, number of sexual partners, history of genital warts, and education level, highlighting a notable public health concern in the region.